April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Screening the DNA of Ocular Albinism Patients for Possible Mutations in GNAI3 (Guanine Nucleotide Binding Protein, Alpha Inhibiting Activity Polypeptide 3 gene)
Author Affiliations & Notes
  • Alejandra Young
    Jules Stein Eye Institute, UCLA, Los Angeles, CA
    Molecular Biology Institute, UCLA, Los Angeles, CA
  • Richard A Lewis
    Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX
  • Debora B Farber
    Jules Stein Eye Institute, UCLA, Los Angeles, CA
    Molecular Biology Institute, UCLA, Los Angeles, CA
  • Footnotes
    Commercial Relationships Alejandra Young, None; Richard Lewis, None; Debora Farber, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 6438. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Alejandra Young, Richard A Lewis, Debora B Farber; Screening the DNA of Ocular Albinism Patients for Possible Mutations in GNAI3 (Guanine Nucleotide Binding Protein, Alpha Inhibiting Activity Polypeptide 3 gene). Invest. Ophthalmol. Vis. Sci. 2014;55(13):6438.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Ocular albinism type 1 (OA) is the most common form of ocular albinism. It has an estimated prevalence of 1/50,000 in the general population of the United States. Although the cutaneous manifestations of OA are very mild, affected patients present abnormal, giant melanosomes in both the RPE and skin and show abnormal crossing of the optic axons at the brain optic chiasm. This disease is caused by mutations in the OA1 gene that encodes a G-protein coupled receptor, OA1, which in the eye is specifically localized to RPE melanosomal membranes. We have previously demonstrated by in-vivo and in-vitro studies on mice that the heterotrimeric G protein Gαi3 signals in the same transduction pathway controlled by Oa1 to regulate melanosomal biogenesis and axonal growth through the optic chiasm. Mutations in the OA1 gene in humans could render the OA1 protein incapable of activating the heterotrimeric Gαi3 on the surface membrane of the melanosome. The same effect would be observed in the absence of Oa1 or Gαi3 in the corresponding knockout mice. We hypothesized that the presence of macromelanosomes in the RPE of ocular albino patients in whom a mutation in OA1 had not been found, might be explained by mutations in GNAI3, the human ortholog of the mouse Gαi3 gene. Thus, the objective of this work was to screen the DNA of this type of OA patients.

Methods: DNA from 26 patients diagnosed with OA and presenting a phenotype consistent with the disease but who did not show mutation(s) in OA1 were tested for mutations in GNAI3. We sequenced the entire GNAI3 gene (~47Kb) using Agilent’s Haloplex Technology. Several primers were designed to amplify the coding region (9 exons), including its upstream 5’ UTR in boundary with the GPR61 gene, and its 3’ UTR bordering the MIR197 gene.

Results: Agilent’s Haloplex sequencing of the 26 OA patients’ DNAs identified several new sequence variants in the 5’ and 3’ UTRs. However, 6 control subjects shared these variants.

Conclusions: Our results show that the sequence variants observed in the 5’ and 3’ UTRs of the GNAI3 gene from the 26 OA patients studied are common in normal humans and, therefore, cannot be the cause of the abnormal phenotype observed in their RPE.

Keywords: 539 genetics • 537 gene screening • 701 retinal pigment epithelium  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×